$CERT News

The Bull Case For Certara (CERT) Could Change Following Wider Q2 Loss And Leadership Shake-Up - Learn Why

Barclays Maintains Equal-Weight on Certara, Raises Price Target to $7.5

Certara (CERT) Q2 2026 Earnings Call Transcript

Certara, Inc. Q2 2026 Earnings Call Summary

Certara, Inc. 2026 Q2 - Results - Earnings Call Presentation

Certara, Inc. (CERT) Q2 2026 Earnings Call Transcript

Certara Q2 Earnings Call Highlights

Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates

Certara Reports Second Quarter 2026 Financial Results

Transcript: Certara Q2 2026 Earnings Conference Call

Certara Lowers FY2026 Adj EPS Guidance from $0.35-$0.41 to $0.31-$0.36 vs $0.38 Est; Lowers FY2026 Sales Guidance from $395.000M-$405.000M to $367.000M-$382.000M vs $398.585M Est

Certara Q2 Adj. EPS $0.08 Misses $0.09 Estimate, Sales $93.271M Miss $98.392M Estimate

Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026

Certara teams up with Nvidia to strengthen AI platform with BioNeMo toolkit (CERT)

Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit

Certara Partners With NVIDIA To Advance Its Open Integrated AI Platform, Unifying Scientific Software, Regulatory Expertise, And Proprietary Datasets With AI-First, Agentic Frameworks

Is Certara (CERT) Quietly Recasting Its Small-Cap Identity Around Biosimulation Advisory Leadership?

Certara (CERT) Stock Sees Fair Value Edges Lower As Analysts Trim Targets

Certara Announces CFO Transition

Certara Outlines AI Push, Cost Cuts and New Growth Engines at Jefferies Conference